Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $13.63, for a total value of $74,828.70. Following the completion of the sale, the insider now directly owns 10,983 shares of the company’s stock, valued at $149,698.29. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Bernard Ravina also recently made the following trade(s):

  • On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The shares were sold at an average price of $13.26, for a total value of $72,797.40.
  • On Tuesday, October 10th, Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock. The shares were sold at an average price of $20.33, for a total value of $223,223.40.

Voyager Therapeutics Inc (NASDAQ VYGR) traded up $1.26 during mid-day trading on Wednesday, reaching $14.62. The company’s stock had a trading volume of 627,278 shares, compared to its average volume of 250,913. Voyager Therapeutics Inc has a fifty-two week low of $8.10 and a fifty-two week high of $25.99.

A number of hedge funds have recently added to or reduced their stakes in the business. Iguana Healthcare Management LLC acquired a new position in Voyager Therapeutics during the 3rd quarter valued at about $515,000. Point72 Asset Management L.P. acquired a new position in Voyager Therapeutics during the 3rd quarter valued at about $2,695,000. Dimensional Fund Advisors LP boosted its stake in Voyager Therapeutics by 7.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock valued at $2,181,000 after purchasing an additional 7,786 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Voyager Therapeutics by 71.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock valued at $1,026,000 after purchasing an additional 20,753 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware acquired a new position in Voyager Therapeutics during the 3rd quarter valued at about $1,412,000. Institutional investors and hedge funds own 35.97% of the company’s stock.

A number of analysts recently commented on VYGR shares. Canaccord Genuity started coverage on Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 target price for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 target price (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Chardan Capital reaffirmed a “hold” rating on shares of Voyager Therapeutics in a research report on Sunday, September 10th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. Voyager Therapeutics currently has an average rating of “Buy” and a consensus price target of $26.33.

WARNING: “Insider Selling: Voyager Therapeutics Inc (VYGR) Insider Sells 5,490 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/13/insider-selling-voyager-therapeutics-inc-vygr-insider-sells-5490-shares-of-stock.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.